Preclinical News and Research

RSS

New clinical trial to evaluate DEX-M74 against hereditary inclusion body myopathy

Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.

25 Sep 2012

Wiley announces publication of 6-volume Encyclopedia of Drug Metabolism and Interactions

Wiley is pleased to announce publication of the state-of-the-art, 6-volume Encyclopedia of Drug Metabolism and Interactions.

25 Sep 2012

Lonafarnib proves effective for children with progeria

Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal "rapid-aging" disease, demonstrate the efficacy of a farnesyltransferase inhibitor (FTI), a drug originally developed to treat cancer. The clinical trial results, completed only six years after scientists identified the cause of Progeria, included significant improvements in weight gain, bone structure and, most importantly, the cardiovascular system, according to The Progeria Research Foundation (PRF) and Boston Children's Hospital.

25 Sep 2012

pSivida reports revenues of $699,000 for fourth quarter 2012

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2012.

25 Sep 2012

Study reveals potential of NIR spectral imaging for intra-operative skin flap assessment

In 2010 breast reconstruction entered the Top Five list of reconstructive procedures in the US, with 93,000 procedures performed, up 8% from 2009, and 18% from 2000. This is among the most common skin flap procedure performed.

24 Sep 2012

Cannabis Science commences CSTATI-1 preclinical studies in Squamous/BCCs, Kaposi's sarcoma

Cannabis Science, a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, is pleased to announce preclinical investigations being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

24 Sep 2012

Sleep medicine and research: an interview with James K. Walsh

There are a variety of sleep medicines. I am going to refer to what are commonly described as hypnotics or sleeping pills. Sleeping pills have been around for a long time.

24 Sep 2012

Bruker to purchase preclinical imaging product portfolio and related assets from Carestream

Carestream Health and Bruker have entered into an agreement for Bruker to purchase the preclinical in-vivo imaging equipment product portfolio and related assets from Carestream's Molecular Imaging business. Financial terms of the agreement are not being disclosed.

24 Sep 2012

Case Western Reserve researcher to identify mechanistic link between psoriasis and CVD

Armed with a new $1.8 million grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, dermatology researcher Nicole Ward, PhD, assistant professor of dermatology and neurosciences at Case Western Reserve School of Medicine, will lead a study examining the link between psoriasis and heart attack and stroke.

21 Sep 2012

MD Anderson introduces Moon Shots Program to reduce cancer deaths

The University of Texas MD Anderson Cancer Center announces the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.

21 Sep 2012

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema

Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, today announced that it has dosed the first patient in a Phase 1b/2a trial of AKB-9778 for the treatment of diabetic macular edema (DME).

20 Sep 2012

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Gamida Cell, a leader in adult stem cell expansion technologies and products, announced today that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company's second pipeline product.

20 Sep 2012

Oxygen Biotherapeutics first quarter net loss increases to $3.6 million

Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing intravenous and topical oxygen-carrier products, today announced results for the fiscal year (FY) 2013 first quarter ended July 31, 2012.

20 Sep 2012

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.

19 Sep 2012

ProImmune launches ProStorm in vitro cytokine release assay

ProImmune Ltd., a leader in services for understanding immune responses, announced today the commercial launch of ProStorm, an in vitro cytokine release assay, which can help assess the likelihood of first infusion reactions to novel therapeutics.

18 Sep 2012

Positive data from Aprea’s APR-246 Phase I/II study on blood or prostate cancer

Aprea today announced positive data from a completed Phase I/II clinical study with its investigational drug APR-246. The results from the study have been published in the Journal of Clinical Oncology.

18 Sep 2012

UCSF-led research team targets physiological factors that lead to asthma attack

A new study that identifies ways to reduce the factors that lead to an asthma attack gives hope to asthma sufferers. A UCSF researcher and his colleagues believe they have found a way to help asthma sufferers by impeding the two most significant biological responses that lead to an asthma attack.

18 Sep 2012

Novel drug combination for patients with NRAS-mutant melanoma

A new study published online in Nature Medicine, led by scientists at The University of Texas MD Anderson Cancer Center, describes the discovery of a novel drug combination aimed at a subset of melanoma patients who currently have no effective therapeutic options.

17 Sep 2012

UMass Amherst develops 'chemical nose' array to detect metastatic cancers

In the fight against cancer, knowing the enemy's exact identity is crucial for diagnosis and treatment, especially in metastatic cancers, those that spread between organs and tissues. Now chemists led by Vincent Rotello at the University of Massachusetts Amherst have developed a rapid, sensitive way to detect microscopic levels of many different metastatic cell types in living tissue. Findings appear in the current issue of the journal ACS Nano.

14 Sep 2012

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James's University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.

12 Sep 2012

Preclinical News and Research

New clinical trial to evaluate DEX-M74 against hereditary inclusion body myopathy

Wiley announces publication of 6-volume Encyclopedia of Drug Metabolism and Interactions

Lonafarnib proves effective for children with progeria

pSivida reports revenues of $699,000 for fourth quarter 2012

Study reveals potential of NIR spectral imaging for intra-operative skin flap assessment

Cannabis Science commences CSTATI-1 preclinical studies in Squamous/BCCs, Kaposi's sarcoma

Sleep medicine and research: an interview with James K. Walsh

Bruker to purchase preclinical imaging product portfolio and related assets from Carestream

Case Western Reserve researcher to identify mechanistic link between psoriasis and CVD

MD Anderson introduces Moon Shots Program to reduce cancer deaths

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Oxygen Biotherapeutics first quarter net loss increases to $3.6 million

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

ProImmune launches ProStorm in vitro cytokine release assay

Positive data from Aprea’s APR-246 Phase I/II study on blood or prostate cancer

UCSF-led research team targets physiological factors that lead to asthma attack

Novel drug combination for patients with NRAS-mutant melanoma

UMass Amherst develops 'chemical nose' array to detect metastatic cancers

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics